New drug combo aims to reboot immune system against tough melanoma
NCT ID NCT04562129
Summary
This study is testing a combination of three immunotherapy drugs (Interleukin-2, ipilimumab, and nivolumab) for people with advanced, inoperable melanoma that has continued to grow despite prior immunotherapy. The goal is to see if this specific sequence and combination can better control the cancer. It is for adults with stage III or IV melanoma whose disease progressed after treatment with drugs like nivolumab or pembrolizumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.